-
Recently published cases of hepatitis among travelers describe a hepatitis patient's evaluation suggesting incomplete protection against hepatitis A following vaccination and unexpected toxicity from an interesting cultural experience. Both of these cases offer some issues for travel medicine practitioners to consider.
-
In this issue: NSAIDs in the elderly; managing GI and CVD risk with NSAIDs; low-dose naltrexone and fibromyalgia; treating glucocorticoid-induced bone loss; FDA Actions.
-
-
Few diseases have anywhere near the clout, exposure, and clinical trial support of HIV/AIDS. Dedicated foundations, advocacy groups, and international organizations have spent more than two decades working to ensure HIV prevention and medication trials are a top priority for governments and private industry.
-
A clinical trial site enrolling for an HIV vaccine trial was successful in its strategies to engage and recruit from a local minority community, a new study shows.
-
-
As often happens with epidemics, the influenza A (H1N1) virus infection that began in Mexico in April started small, but jumped across the North American continent with breathtaking speed.
-
Clinical trial professionals who would like guidelines for working with communities during study enrollment might look no further than the 10 fundamental principles created for HIV biomedical prevention research.
-
For many clinical trials developing a community advisory board (CAB) is the right thing to do for the local community and for eventual participants. But it's also the right strategy for investigators, who otherwise might miss cues about problems with their protocol design and participant education.
-
When a phase IIb clinical trial site needed to ensure minority enrollment in an HIV vaccine trial, CT staff and investigators tried a variety of successful methods to engage and educate the targeted community.
